Equillium Inc (EQ)
1.69
-0.10
(-5.59%)
USD |
NASDAQ |
May 08, 16:00
1.69
0.00 (0.00%)
After-Hours: 16:11
Equillium Enterprise Value: 22.24M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 22.24M |
May 06, 2024 | 19.77M |
May 03, 2024 | 18.01M |
May 02, 2024 | 14.13M |
May 01, 2024 | 10.61M |
April 30, 2024 | 11.66M |
April 29, 2024 | 16.60M |
April 26, 2024 | 19.42M |
April 25, 2024 | 22.95M |
April 24, 2024 | 22.24M |
April 23, 2024 | 19.77M |
April 22, 2024 | 17.30M |
April 19, 2024 | 15.89M |
April 18, 2024 | 20.12M |
April 17, 2024 | 22.24M |
April 16, 2024 | 24.36M |
April 15, 2024 | 21.54M |
April 12, 2024 | 24.36M |
April 11, 2024 | 27.88M |
April 10, 2024 | 24.71M |
April 09, 2024 | 27.53M |
April 08, 2024 | 26.82M |
April 05, 2024 | 34.40M |
April 04, 2024 | 37.40M |
April 03, 2024 | 41.28M |
Date | Value |
---|---|
April 02, 2024 | 35.99M |
April 01, 2024 | 33.52M |
March 28, 2024 | 40.57M |
March 27, 2024 | 31.76M |
March 26, 2024 | 31.76M |
March 25, 2024 | 45.16M |
March 22, 2024 | 58.55M |
March 21, 2024 | 56.79M |
March 20, 2024 | 60.67M |
March 19, 2024 | 53.97M |
March 18, 2024 | 52.21M |
March 15, 2024 | 48.68M |
March 14, 2024 | 49.03M |
March 13, 2024 | 51.85M |
March 12, 2024 | 48.33M |
March 11, 2024 | 48.33M |
March 08, 2024 | 53.26M |
March 07, 2024 | 54.67M |
March 06, 2024 | 38.81M |
March 05, 2024 | 38.10M |
March 04, 2024 | 37.75M |
March 01, 2024 | 47.27M |
February 29, 2024 | 46.92M |
February 28, 2024 | 50.80M |
February 27, 2024 | 47.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-42.77M
Minimum
Mar 10 2023
436.89M
Maximum
Jul 13 2020
35.71M
Average
30.01M
Median
Jul 06 2022
Enterprise Value Benchmarks
Janux Therapeutics Inc | 2.830B |
Mersana Therapeutics Inc | 247.47M |
Vera Therapeutics Inc | 2.341B |
Jasper Therapeutics Inc | 256.12M |
PepGen Inc | 342.57M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -2.342M |
Revenue (Quarterly) | 9.211M |
Total Expenses (Quarterly) | 12.41M |
EPS Diluted (Quarterly) | -0.07 |
Profit Margin (Quarterly) | -25.43% |
Earnings Yield | -23.08% |
Normalized Earnings Yield | -23.08 |